Should I buy or sell Sana Biotechnology stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sana Biotechnology in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SANA shares. View SANA analyst ratings or view top-rated stocks .

What is Sana Biotechnology's stock price target for 2024?

4 analysts have issued 1-year price targets for Sana Biotechnology's shares. Their SANA share price targets range from $8.00 to $15.00. On average, they predict the company's share price to reach $11.67 in the next twelve months. This suggests a possible upside of 56.2% from the stock's current price. View analysts price targets for SANA or view top-rated stocks among Wall Street analysts .

How have SANA shares performed in 2024?

Sana Biotechnology's stock was trading at $4.08 at the start of the year. Since then, SANA stock has increased by 83.1% and is now trading at $7.47. View the best growth stocks for 2024 here .

When is Sana Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our SANA earnings forecast .

How were Sana Biotechnology's earnings last quarter?

Sana Biotechnology, Inc. (NASDAQ:SANA) announced its quarterly earnings data on Thursday, February, 29th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.03. During the same quarter in the previous year, the business earned ($0.40) EPS.

What ETFs hold Sana Biotechnology's stock?

ETFs with the largest weight of Sana Biotechnology (NASDAQ:SANA) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) and iShares Genomics Immunology and Healthcare ETF (IDNA) . IQ Chaikin U.S. Small Cap ETF (CSML) .

When did Sana Biotechnology IPO?

Sana Biotechnology (SANA) raised $322 million in an initial public offering (IPO) on Thursday, February 4th 2021. The company issued 15,000,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities acted as the underwriters for the IPO.

Who are Sana Biotechnology's major shareholders?

Sana Biotechnology's stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.03%). Insiders that own company stock include Christian Hordo , James J Macdonald, Joshua H Bilenker, Patrick Y Yang, Robert Nelsen and Ventures Fund V Gener Flagship. View institutional ownership trends .

How do I buy shares of Sana Biotechnology?

Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SANA

Sana Biotechnology (SANA) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free SANA Stock Alerts

$7.32

-0.41 (-5.30%)

(As of 03:10 PM ET)

Compare

Today's Range: $7.25
▼
$7.84
50-Day Range: $6.27
▼
$11.27
52-Week Range: $2.74
▼
$12.00

Volume: 2.47 million shs
Average Volume: 3.09 million shs
Market Capitalization: $1.61 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.67

Get Sana Biotechnology alerts:

Sana Biotechnology MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 56.2% Upside
$11.67 Price Target
Short Interest: Bearish
22.16% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$10 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.02) to ($0.85) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.27 out of 5 stars

Medical Sector

621st out of 918 stocks

Biological Products, Except Diagnostic Industry

103rd out of 151 stocks

3.4

Analyst's Opinion

Consensus Rating
Sana Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Sana Biotechnology has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
22.16% of the float of Sana Biotechnology has been sold short.
Short Interest Ratio / Days to Cover
Sana Biotechnology has a short interest ratio ("days to cover") of 7.9.
Change versus previous month
Short interest in Sana Biotechnology has recently increased by 5.88%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Sana Biotechnology does not currently pay a dividend.
Dividend Growth
Sana Biotechnology does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SANA.

1.4

News and Social Media Coverage

News Sentiment
Sana Biotechnology has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Sana Biotechnology this week, compared to 2 articles on an average week.
Search Interest
Only 6 people have searched for SANA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sana Biotechnology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,999,996.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
34.90% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
88.23% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Sana Biotechnology are expected to grow in the coming year, from ($1.02) to ($0.85) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sana Biotechnology is -5.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sana Biotechnology is -5.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sana Biotechnology has a P/B Ratio of 5.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Sana Biotechnology Stock (NASDAQ:SANA)

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

SANA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SANA Stock News Headlines

March 17, 2024 | seekingalpha.com

Sana Biotechnology: Now In Overbought Territory

March 16, 2024 | finance.yahoo.com

SANA Apr 2024 15.000 call

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 14, 2024 | finance.yahoo.com

J&J, Novo support Asgard’s push to make ‘in vivo’ cell therapies

March 11, 2024 | finance.yahoo.com

Director Patrick Yang Sells 25,000 Shares of Sana Biotechnology Inc (SANA)

March 7, 2024 | finance.yahoo.com

Baillie Gifford Bolsters Stake in Sana Biotechnology Inc

March 1, 2024 | markets.businessinsider.com

Sana Biotechnology: Buy Rating Affirmed Amid Anticipation of Clinical Breakthroughs and Hypoimmune Platform Validation

March 1, 2024 | markets.businessinsider.com

Sana Biotechnology: Promising Clinical Prospects and Buy Rating Justified by Upcoming Data Readouts

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 1, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Privia Health Group (PRVA) and Sana Biotechnology (SANA)

February 29, 2024 | globenewswire.com

Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

February 28, 2024 | globenewswire.com

Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference

February 19, 2024 | finance.yahoo.com

Institutional investors are Sana Biotechnology, Inc.'s (NASDAQ:SANA) biggest bettors and were rewarded after last week's US$521m market cap gain

February 18, 2024 | 247wallst.com

Insider Buying: Taking a Controlling Stake in a Struggling Retailer?

February 13, 2024 | finance.yahoo.com

Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP

February 12, 2024 | finance.yahoo.com

Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

February 9, 2024 | msn.com

Sana Biotechnology Announces Pricing of Upcoming Offering

February 9, 2024 | msn.com

Sana Biotechnology’s Major Public Offering Agreement

February 8, 2024 | bizjournals.com

Sana Biotechnology raising $165M through public offering

February 8, 2024 | msn.com

Sana Biotechnology Previews Preliminary Financials and Trial Progress

February 8, 2024 | msn.com

Sana Biotechnology down 5%, prices $165M offering

February 8, 2024 | markets.businessinsider.com

Sana Biotechnology Prices Upsized Public Offering Of $165 Mln Of Shares

February 8, 2024 | finance.yahoo.com

Sana Biotechnology Announces Pricing of Upsized Public Offering

February 7, 2024 | marketwatch.com

Sana Biotechnology Shares Fall After Public Offering News

February 7, 2024 | finance.yahoo.com

Sana Biotechnology Announces Proposed Public Offering of Common Stock

February 1, 2024 | benzinga.com

Sana Biotechnology Stock (NASDAQ:SANA) Dividends: History, Yield and Dates

January 28, 2024 | finance.yahoo.com

Baillie Gifford Reduces Stake in Sana Biotechnology Inc

See More Headlines

Receive SANA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:SANA
CUSIP: N/A
CIK: 1770121
Web: sana.com
Phone: 206-701-7914
Fax: N/A
Employees: 328
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.67
High Stock Price Target: $15.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +53.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-283,260,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -88.36%
Return on Assets: -47.89%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.31
Quick Ratio: 3.31

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.46 per share
Price / Book: 5.21

Miscellaneous

Outstanding Shares: 220,450,000
Free Float: 143,512,000
Market Cap: $1.68 billion
Optionable: Optionable
Beta: 1.61

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Steven D. Harr M.D. (Age 54)
President, CEO & Director
Comp: $1.04M
Mr. Bernard J. Cassidy J.D. (Age 69)
Executive VP, General Counsel & Corporate Secretary
Comp: $491.39k
Mr. Nathan Hardy M.B.A. (Age 48)
Executive VP & CFO
Comp: $683.49k
Dr. Edward Rebar Ph.D. (Age 56)
Senior VP & CTO
Ms. Robin Andrulevich (Age 58)
Executive VP & Chief People Officer
Mr. Paul Brunetta M.D.
Senior VP and Head of Clinical & Translational Science
Mr. Christian Hordo M.B.A. (Age 41)
Executive VP & Chief Business Officer
Comp: $485.03k
Dr. Sonja Schrepfer M.D. (Age 49)
Ph.D., Senior VP & Head of Hypoimmune Platform
Dr. Terry Fry M.D. (Age 57)
Senior VP & Head of T Cell Therapeutics
Dr. Steven A. Goldman M.D. (Age 66)
Ph.D., Senior VP & Head of CNS Therapy

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SANA Stock Analysis - Frequently Asked Questions

Should I buy or sell Sana Biotechnology stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sana Biotechnology in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SANA shares.
View SANA analyst ratings or view top-rated stocks.
What is Sana Biotechnology's stock price target for 2024?: 4 analysts have issued 1-year price targets for Sana Biotechnology's shares. Their SANA share price targets range from $8.00 to $15.00. On average, they predict the company's share price to reach $11.67 in the next twelve months. This suggests a possible upside of 56.2% from the stock's current price.
View analysts price targets for SANA or view top-rated stocks among Wall Street analysts.
How have SANA shares performed in 2024?: Sana Biotechnology's stock was trading at $4.08 at the start of the year. Since then, SANA stock has increased by 83.1% and is now trading at $7.47.
View the best growth stocks for 2024 here.
When is Sana Biotechnology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our SANA earnings forecast.
How were Sana Biotechnology's earnings last quarter?: Sana Biotechnology, Inc. (NASDAQ:SANA) announced its quarterly earnings data on Thursday, February, 29th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.03. During the same quarter in the previous year, the business earned ($0.40) EPS.

What ETFs hold Sana Biotechnology's stock?: ETFs with the largest weight of Sana Biotechnology (NASDAQ:SANA) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) and iShares Genomics Immunology and Healthcare ETF (IDNA).IQ Chaikin U.S. Small Cap ETF (CSML).
When did Sana Biotechnology IPO?: Sana Biotechnology (SANA) raised $322 million in an initial public offering (IPO) on Thursday, February 4th 2021. The company issued 15,000,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities acted as the underwriters for the IPO.
Who are Sana Biotechnology's major shareholders?: Sana Biotechnology's stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.03%). Insiders that own company stock include Christian Hordo, James J Macdonald, Joshua H Bilenker, Patrick Y Yang, Robert Nelsen and Ventures Fund V Gener Flagship.
View institutional ownership trends.
How do I buy shares of Sana Biotechnology?: Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SANA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Sana Biotechnology (SANA) Stock Price, News & Analysis

Sana Biotechnology MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Sana Biotechnology Stock (NASDAQ:SANA)

SANA Stock Price History

SANA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

SANA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™